Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway

Toxicology Letters

Volumn 220, Issue 3, 2013, Pages 219-228

  Li, Hongzhong ^a   Yang, Bing ^a   Huang, Jing ^a   Xiang, Tingxiu ^a   Yin, Xuedong ^a   Wan, Jingyuan ^b   Luo, Fuling ^b   Zhang, Li ^b   Li, Hongyuan ^a   Ren, Guosheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Catenin; Apoptosis; Breast cancer; Flavonoid; Naringin

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; AURANTIIN; BETA CATENIN; PROTEIN P21; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SCREENING; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; APOPTOSIS; BETA CATENIN; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLAVANONES; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, SCID; RANDOM ALLOCATION; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CITRUS; MUS;

EID: 84879519304     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.05.006     Document Type: Article

References (47)

1. Adams L.S., Phung S., Yee N., Seeram N.P., Li L., Chen S. Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Research 2010, 70:3594-3605.
2. Bottazzi M.E., Zhu X., Bohmer R.M., Assoian R.K. Regulation of p21(cip1) expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase. Journal of Cell Biology 1999, 146:1255-1264.
3. Calaf G.M., Alvarado M.E., Hei T.K. Beta catenin is associated with breast cancer progression in vitro. International Journal of Oncology 2005, 26:913-921.
4. Cayrol C., Knibiehler M., Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998, 16:311-320.
5. Choi Y.H., Yoo Y.H. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncology Reports 2012, 28:2163-2169.
6. Church D.N., Talbot D.C. Survivin in solid tumors: rationale for development of inhibitors. Current Oncology Reports 2012, 14:120-128.
7. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA: A Cancer Journal for Clinicians 2011, 61:409-418.
8. Favaloro B., Allocati N., Graziano V., Di Ilio C., De Laurenzi V. Role of apoptosis in disease. Aging (Albany, NY) 2012, 4:330-349.
9. Fuhr U., Kummert A.L. The fate of naringin in humans: a key to grapefruit juice-drug interactions?. Clinical Pharmacology and Therapeutics 1995, 58:365-373.
10. Gareau C., Fournier M.J., Filion C., Coudert L., Martel D., Labelle Y., Mazroui R. p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis. PLoS ONE 2011, 6:e20254.
11. Geyer F.C., Lacroix-Triki M., Savage K., Arnedos M., Lambros M.B., MacKay A., Natrajan R., Reis-Filho J.S. beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Modern Pathology 2011, 24:209-231.
12. Irvin W.J., Carey L.A. What is triple-negative breast cancer?. European Journal of Cancer 2008, 44:2799-2805.
13. Kamei J., Toyofuku T., Hori M. Negative regulation of p21 by beta-catenin/TCF signaling: a novel mechanism by which cell adhesion molecules regulate cell proliferation. Biochemical and Biophysical Research Communications 2003, 312:380-387.
14. Kanno S., Tomizawa A., Hiura T., Osanai Y., Shouji A., Ujibe M., Ohtake T., Kimura K., Ishikawa M. Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biological & Pharmaceutical Bulletin 2005, 28:527-530.
15. Kim D.I., Lee S.J., Lee S.B., Park K., Kim W.J., Moon S.K. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis 2008, 29:1701-1709.
16. King T.D., Suto M.J., Li Y. The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. Journal of Cellular Biochemistry 2012, 113:13-18.
17. Kumar A., Prakash A., Dogra S. Naringin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress induced by d-galactose in mice. Food and Chemical Toxicology 2010, 48:626-632.
18. Lee E.J., Moon G.S., Choi W.S., Kim W.J., Moon S.K. Naringin-induced p21WAF1-mediated G(1)-phase cell cycle arrest via activation of the Ras/Raf/ERK signaling pathway in vascular smooth muscle cells. Food and Chemical Toxicology 2008, 46:3800-3807.
19. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
20. Luo J., Deng Z.L., Luo X., Tang N., Song W.X., Chen J., Sharff K.A., Luu H.H., Haydon R.C., Kinzler K.W., Vogelstein B., He T.C. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nature Protocols 2007, 2:1236-1247.
21. Lv Y.G., Yu F., Yao Q., Chen J.H., Wang L. The role of survivin in diagnosis, prognosis and treatment of breast cancer. Journal of Thoracic Disease 2010, 2:100-110.
22. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes and Development 1995, 9:935-944.
23. Meiyanto, Hermawan E., Anindyajati A. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pacific Journal of Cancer Prevention 2012, 13:427-436.
24. Nagaraj N.S., Anilakumar K.R., Singh O.V. Diallyl disulfide causes caspase-dependent apoptosis in human cancer cells through a Bax-triggered mitochondrial pathway. The Journal of Nutritional Biochemistry 2010, 21:405-412.
25. Nakopoulou L., Gakiopoulou-Givalou H., Karayiannakis A.J., Giannopoulou I., Keramopoulos A., Davaris P., Pignatelli M. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002, 40:536-546.
26. Nie Y.C., Wu H., Li P.B., Luo Y.L., Long K., Xie L.M., Shen J.G., Su W.W. Anti-inflammatory effects of naringin in chronic pulmonary neutrophilic inflammation in cigarette smoke-exposed rats. Journal of Medicinal Food 2012, 15:894-900.
27. Olmeda D., Castel S., Vilaro S., Cano A. Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Molecular Biology of the Cell 2003, 14:2844-2860.
28. Olsson M., Zhivotovsky B. Caspases and cancer. Cell Death and Differentiation 2011, 18:1441-1449.
29. Prosperi J.R., Goss K.H. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Current Drug Targets 2010, 11:1074-1088.
30. Quasnichka H., Slater S.C., Beeching C.A., Boehm M., Sala-Newby G.B., George S.J. Regulation of smooth muscle cell proliferation by beta-catenin/T-cell factor signaling involves modulation of cyclin D1 and p21 expression. Circulation Research 2006, 99:1329-1337.
31. Ramesh E., Alshatwi A.A. Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food and Chemical Toxicology 2012, 51C:97-105.
32. Ray R.B., Raychoudhuri A., Steele R., Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Research 2010, 70:1925-1931.
33. Reddy K.B. Triple-negative breast cancers: an updated review on treatment options. Current Oncology 2011, 18:e173-e179.
34. Rodel F., Sprenger T., Kaina B., Liersch T., Rodel C., Fulda S., Hehlgans S. Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Current Medicinal Chemistry 2012, 19:3679-3688.
35. Seo Y.J., Kim B.S., Chun S.Y., Park Y.K., Kang K.S., Kwon T.G. Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1. Journal of Korean Medical Science 2011, 26:1489-1494.
36. Siegelin M.D., Reuss D.E., Habel A., Herold-Mende C., von Deimling A. The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. Molecular Cancer Therapeutics 2008, 7:3566-3574.
37. Sun S.H., Huang H.C., Huang C., Lin J.K. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. European Journal of Pharmacology 2012, 690:22-30.
38. Tapia J.C., Torres V.A., Rodriguez D.A., Leyton L., Quest A.F. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:15079-15084.
39. Tourniaire F., Hassan M., Andre M., Ghiringhelli O., Alquier C., Amiot M.J. Molecular mechanisms of the naringin low uptake by intestinal Caco-2 cells. Molecular Nutrition & Food Research 2005, 49:957-962.
40. Wang L., Lu A., Liu X., Sang M., Shan B., Meng F., Cao Q., Ji X. The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via beta-catenin-dependent signaling. Oncology Reports 2011, 26:1149-1156.
41. Wang S., Kang W., Go M.Y., Tong J.H., Li L., Zhang N., Tao Q., Li X., To K.F., Sung J.J., Yu J. Dapper homolog 1 is a novel tumor suppressor in gastric cancer through inhibiting the nuclear factor-kappaB signaling pathway. Molecular Medicine 2012, 18:1402-1411.
42. Weiss R.H. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003, 4:425-429.
43. Williams G.H., Stoeber K. The cell cycle and cancer. Journal of Pathology 2012, 226:352-364.
44. Xulu S., Oroma Owira P.M. Naringin ameliorates atherogenic dyslipidemia but not hyperglycemia in rats with type 1 diabetes. Journal of Cardiovascular Pharmacology 2012, 59:133-141.
45. Zandi K., Teoh B.T., Sam S.S., Wong P.F., Mustafa M.R., Abubakar S. Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virology Journal 2011, 8:560.
46. Zhang J., Sun C., Yan Y., Chen Q., Luo F., Zhu X., Li X., Chen K. Purification of naringin and neohesperidin from Huyou (Citrus changshanensis) fruit and their effects on glucose consumption in human HepG2 cells. Food Chemistry 2012, 135:1471-1478.
47. Zhu H., Zhang G., Wang Y., Xu N., He S., Zhang W., Chen M., Liu M., Quan L., Bai J. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. Cancer Science 2010, 101:1156-1162.